Recent 8-K filings for BRTX
Highest-materiality recent filing
BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects
- Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
- Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).
-
CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
-
Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
-
BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired
Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
-
BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement
Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
-
BioRestorative Therapies restates financials due to warrant classification error; no cash impact
Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
-
BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting
Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.78 · Median 0.50 · Most common event other_material